Elixir drops IPO, Aldagen launches IPO
Elixir Pharmaceuticals has dropped its bid for an $86 million IPO, saying that market conditions aren't right. At the same time, Aldagen, a small biotech company with 18 employees, is making a bid to raise $80 million in an IPO. Aldagen is developing adult stem cell therapies.
The News & Observer notes that if Aldagen is successful, it will raise new funds for research while setting up an exit for its investors. The developer was set up in 2000 to exploit new research at Duke.
- check out the report on Elixir
- see Aldagen's release and read the story for more
Related Articles:
Aldagen gets $18.4M in fourth round
Aldagen adds $9M in new venture funds
Aldagen gains $17.3M in financing
Elixir Pharmaceuticals plans $86.25M IPO
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
